Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022
Details : TQS-168 is a PGC-1a-enhancing small molecule in development for the treatment of neurodegenerative, metabolic, and aging-related diseases in which PGC-1a modulation plays a critical role.
Brand Name : TQS-168
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2022
Details : TQS-168, a small molecule modulator of PGC-1a, for the treatment of amyotrophic lateral sclerosis (ALS). TQS-168 showed survival and functional benefits in various animal models of neurodegenerative disease, including ALS and Parkinson’s disease.
Brand Name : TQS-168
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 21, 2022
Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168
Details : The data from our Phase 1 study of TQS-168, a small molecule modulator of PGC-1a demonstrate that target plasma exposures can be achieved at dose levels that are well tolerated.
Brand Name : TQS-168
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 02, 2022
Lead Product(s) : TQS-168
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Remiges Ventures
Deal Size : $30.0 million
Deal Type : Series A Financing
Details : The financing will support company's novel platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorde...
Brand Name : TQS-168
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 09, 2020
Lead Product(s) : TQS-168
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Remiges Ventures
Deal Size : $30.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?